Eyal C. Attar
2021
In 2021, Eyal C. Attar earned a total compensation of $1.9M as Chief Medical Officer at Aprea Therapeutics, a 4% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $180,000 |
|---|---|
| Option Awards | $627,770 |
| Salary | $450,882 |
| Stock Awards | $648,000 |
| Total | $1,906,652 |
Attar received $648K in stock awards, accounting for 34% of the total pay in 2021.
Attar also received $180K in non-equity incentive plan, $627.8K in option awards and $450.9K in salary.
Rankings
In 2021, Eyal C. Attar's compensation ranked 6,211th out of 12,415 executives tracked by ExecPay. In other words, Attar earned more than 50.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 6,211 out of 12,415 | 50th |
Division Manufacturing | 2,631 out of 5,505 | 52nd |
Major group Chemicals And Allied Products | 1,149 out of 2,375 | 52nd |
Industry group Drugs | 1,022 out of 2,096 | 51st |
Industry Pharmaceutical Preparations | 740 out of 1,546 | 52nd |
Source: SEC filing on June 10, 2022.
Attar's colleagues
We found three more compensation records of executives who worked with Eyal C. Attar at Aprea Therapeutics in 2021.
News
Aprea Therapeutics CEO Christian Schade's 2022 pay falls 58% to $1.4M
July 11, 2023
Aprea Therapeutics CEO Christian Schade's 2021 pay slips 17% to $3.2M
June 10, 2022
Aprea Therapeutics CEO Christian Schade's 2020 pay rises 6% to $3.9M
April 28, 2021
Aprea Therapeutics CEO Christian Schade's 2019 pay jumps 520% to $3.7M
April 29, 2020